Ticker: ICE

Intercontinental Exchange

Finance Financials Financial - Data & Stock Exchanges
Price 145.79
Reco Hold Potential 63 Risk 46 Updated 2026-07-27

Forecast impact

negative
Target +30.3% target fill 76.7%
Reaction D5 -4.56% · D10 pending market trust
Impact Potential -4 · Risk +3 valid until 2026-08-14

Track in portfolio

Price chart

AI recommendation Analyst forecast Calendar event Positive signal Negative signal Neutral / update Hold / informational B My buy S My sell
Description

Company and Business Model

Intercontinental Exchange (ICE) operates as a global financial marketplace, providing trading, clearing, and data services. Its core products include futures and options contracts, as well as various financial data services. Major business segments encompass exchanges, clearing houses, and data services, with primary revenue sources derived from transaction fees, market data sales, and listing services. The company serves a diverse clientele, including financial institutions, corporations, and individual investors.

Investment Profile

The investment profile of Intercontinental Exchange is more aligned with balanced investors, given its combination of growth potential and moderate dividend yield. The stock exhibits stable revenue growth and a consistent earnings performance, appealing to those seeking both capital appreciation and income. Its relatively low volatility further supports a balanced investment approach.

Fundamental metrics (experimental) Updated: 2026-07-27
EPS (TTM) — earnings per share for the last 12 months, $
6.90
Revenue QoQ — quarter-over-quarter revenue growth
16.8%
EPS surprise
1.8%
20d volatility
1.5%
Dividend yield
2.5%
last ex-date
2026-12-16
AI recommendation changes
Date Before After Reason
2026-07-23 Sell Hold Strong revenue growth, but mixed momentum signals.
2026-07-15 Hold Sell Mixed performance; cautious outlook amid market pressures.
2026-07-07 Sell Hold Mixed momentum; solid fundamentals but recent declines raise concerns.
Analyst forecasts
Date Analyst Action Target Price Then
2026-07-15 Piper Sandler Target Lowered 211 → 190 137.61
2026-07-10 Morgan Stanley Target Lowered 187 → 163 135.755
2026-07-09 Barclays Target Lowered 201 → 180 133.08
News Page 1 of 1
Accenture Intercontinental Exchange Medtronic Abbott Laboratories

Analysts recommend buying dividend stocks like Abbott Laboratories (ABT) and Accenture (ACN) for portfolio income in 2026

In a high-priced stock market, investors are increasingly looking for undervalued dividend stocks that provide income while they wait for potential price appreciation. This strategy is particularly relevant given the current market volatility and inflation concerns.